JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB106377

Anti-ATOH8 antibody

Be the first to review this product! Submit a review

|

(5 Publications)

Rabbit Polyclonal ATOH8 antibody. Suitable for WB and reacts with Mouse samples. Cited in 5 publications. Immunogen corresponding to Synthetic Peptide within Human ATOH8.

View Alternative Names

ATH6, BHLHA21, ATOH8, Transcription factor ATOH8, Class A basic helix-loop-helix protein 21, Helix-loop-helix protein hATH-6, Protein atonal homolog 8, bHLHa21, hATH6

1 Images
Western blot - Anti-ATOH8 antibody (AB106377)
  • WB

Unknown

Western blot - Anti-ATOH8 antibody (AB106377)

Lane 1:

Western blot - Anti-ATOH8 antibody (ab106377) at 1 µg/mL

Lane 2:

Western blot - Anti-ATOH8 antibody (ab106377) at 2 µg/mL

All lanes:

A-20 cell lysate at 15 µg

Predicted band size: 34 kDa

false

Key facts

Host species

Rabbit

Clonality

Polyclonal

Isotype

IgG

Carrier free

No

Reacts with

Mouse

Applications

WB

applications

Immunogen

Synthetic Peptide within Human ATOH8. The exact immunogen used to generate this antibody is proprietary information.

Q96SQ7

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Mouse": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1-2 µg/mL", "WB-species-notes": "<p></p>" } } }

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Immunogen
Storage buffer
pH: 7.2 Preservative: 0.02% Sodium azide Constituents: PBS
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

ATOH8 also known by its alternate name Math6 is a basic helix-loop-helix (bHLH) transcription factor with a mass of approximately 27 kDa. It functions by binding DNA at E-box motifs which influences the transcription of downstream genes. ATOH8 is expressed in various tissues including the brain kidney and muscle indicating its involvement in diverse biological processes. Its expression patterns suggest a role in regulating tissue-specific differentiation and development.
Biological function summary

ATOH8 influences cellular differentiation and development. ATOH8's activity affects muscle and neuronal differentiation implying its potential role in organogenesis and morphogenesis. It does not appear to function as part of a larger protein complex but instead acts as a standalone factor. ATOH8 can modulate expressions of key transcriptional regulators which supports its relevance in developing tissue-specific functions in multiple organ systems.

Pathways

ATOH8 participates in the regulation of signalling cascades involved in development and homeostasis. It is relevant in the TGF-beta/SMAD pathway influencing cell proliferation and differentiation signals alongside related proteins like SMAD2 and SMAD3. Additionally involvement in the Notch signalling pathway aligns ATOH8 with other bHLH factors contributing to its role in regulating gene expression during cell lineage specification.

Research indicates that ATOH8 may impact the progression of muscular dystrophies and certain neural conditions. In muscular dystrophies a potential interaction involves proteins such as myogenin with ATOH8 altering expression patterns during muscle regeneration. In neural disorders dysregulation of ATOH8 may connect to imbalances in neural differentiation potentially influencing pathologies linked to neurodevelopmental disorders. This suggests that ATOH8 might serve as a molecular target for therapeutic research in these areas.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Transcription factor that binds a palindromic (canonical) core consensus DNA sequence 5'-CANNTG- 3' known as an E-box element, possibly as a heterodimer with other bHLH proteins (PubMed : 24236640). Regulates endothelial cell proliferation, migration and tube-like structures formation (PubMed : 24463812). Modulates endothelial cell differentiation through NOS3 (PubMed : 24463812). May be implicated in specification and differentiation of neuronal cell lineages in the brain (By similarity). May participate in kidney development and may be involved in podocyte differentiation (By similarity). During early embryonic development is involved in tissue-specific differentiation processes that are dependent on class II bHLH factors and namely modulates the differentiation program initiated by the pro-endocrine factor NEUROG3 (By similarity). During myogenesis, may play a role during the transition of myoblasts from the proliferative phase to the differentiation phase (By similarity). Positively regulates HAMP transcription in two ways, firstly by acting directly on the HAMP promoter via E-boxes binding and indirectly through increased phosphorylation of SMAD protein complex (PubMed : 24236640). Repress NEUROG3-dependent gene activation in a gene-specific manner through at least two mechanisms; requires only either the sequestering of a general partner such as TCF3 through heterodimerization, either also requires binding of the bHLH domain to DNA via a basic motif (By similarity).
See full target information ATOH8

Publications (5)

Recent publications for all applications. Explore the full list and refine your search

American journal of cancer research 10:3194-3211 PubMed33163265

2020

CYP3A5 suppresses metastasis of lung adenocarcinoma through ATOH8/Smad1 axis.

Applications

Unspecified application

Species

Unspecified reactive species

Qixing Mao,Lin Wang,Yingkuan Liang,Gaochao Dong,Wenjie Xia,Jianzhong Hu,Lin Xu,Feng Jiang

International journal of clinical and experimental 13:2534-2543 PubMed33165366

2020

ATOH8 overexpression inhibits the tumor progression and monocyte chemotaxis in hepatocellular carcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Liping Chen,Jingmao Yang,Yajie Wang,Nana Wu,Xian Li,Jun Li,Yangqing Huang,Jilin Cheng

Oncology reports 37:2955-2963 PubMed28393252

2017

High expression of atonal homolog 8 predicts a poor clinical outcome in patients with colorectal cancer and contributes to tumor progression.

Applications

Unspecified application

Species

Unspecified reactive species

Mengsi Ye,Yun He,Hao Lin,Shouxing Yang,Yuhui Zhou,Lingling Zhou,Jinwei Zhong,Guangrong Lu,Jihang Zheng,Zhan-Xiong Xue,Zhen-Zhai Cai

Oncotarget 7:26765-79 PubMed27049918

2016

Downregulation of ATOH8 induced by EBV-encoded LMP1 contributes to the malignant phenotype of nasopharyngeal carcinoma.

Applications

WB

Species

Unspecified reactive species

Zifeng Wang,Jiajun Xie,Min Yan,Jing Wang,Xi Wang,Jialiang Zhang,Yan Zhang,Pengfei Li,Xinxing Lei,Qitao Huang,Suxia Lin,Xiang Guo,Quentin Liu

Journal of cell science 127:1428-40 PubMed24463812

2014

The role of Hath6, a newly identified shear-stress-responsive transcription factor, in endothelial cell differentiation and function.

Applications

WB

Species

Human

Fang Fang,Scott M Wasserman,Jesus Torres-Vazquez,Brant Weinstein,Feng Cao,Zongjin Li,Kitchener D Wilson,Wen Yue,Joseph C Wu,Xiaoyan Xie,Xuetao Pei
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com